{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:43:34Z","timestamp":1787953414445,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40262-019-00767-z","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T02:20:39Z","timestamp":1556850039000},"page":"1149-1153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-935X","authenticated-orcid":false,"given":"Matthew W.","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"2","key":"767_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/jm201465w","volume":"55","author":"XY Xiao","year":"2012","unstructured":"Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, et al. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012;55(2):597\u2013605.","journal-title":"J Med Chem"},{"key":"767_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecoenv.2018.03.041","volume":"156","author":"Y Kang","year":"2018","unstructured":"Kang Y, Li Q, Mei L, Zhao H, Bai Y, Shen M, et al. Tetracycline resistance genes are more prevalent in wet soils than in dry soils. Ecotoxicol Environ Saf. 2018;156:337\u201343.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"14","key":"767_CR3","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1021\/acs.jmedchem.5b00391","volume":"58","author":"KM Nelson","year":"2015","unstructured":"Nelson KM, Viswanathan K, Dawadi S, Duckworth BP, Boshoff HI, Barry CE, et al. Synthesis and pharmacokinetic evaluation of siderophore biosynthesis inhibitors for Mycobacterium tuberculosis. J Med Chem. 2015;58(14):5459\u201375.","journal-title":"J Med Chem"},{"issue":"3","key":"767_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59(3):1802\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"767_CR5","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"767_CR6","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, Starosta AL, Fyfe C, O\u2019Brien W, Rothstein DM, Mikolajka A, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"767_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02206-17","author":"DR Snydman","year":"2018","unstructured":"Snydman DR, McDermott LA, Jacobus NV, Kerstein K, Grossman TH, Sutcliffe JA. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2018. \nhttps:\/\/doi.org\/10.1128\/aac.02206-17\n\n.","journal-title":"Antimicrob Agents Chemother"},{"key":"767_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00250-17","author":"M Zhao","year":"2017","unstructured":"Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother. 2017. \nhttps:\/\/doi.org\/10.1128\/aac.00250-17\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"767_CR9","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1128\/AAC.00240-16","volume":"60","author":"AK Thabit","year":"2016","unstructured":"Thabit AK, Monogue ML, Nicolau DP. Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother. 2016;60(8):5072\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"767_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00275-18","author":"V Petraitis","year":"2018","unstructured":"Petraitis V, Petraitiene R, Maung BBW, Khan F, Alisauskaite I, Olesky M, et al. Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits. Antimicrob Agents Chemother. 2018. \nhttps:\/\/doi.org\/10.1128\/aac.00275-18\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"767_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.02036-13","volume":"58","author":"KP Connors","year":"2014","unstructured":"Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"767_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/QCO.0000000000000438","volume":"31","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Vena A, Castaldo N, Righi E, Peghin M. New antibiotics for ventilator-associated pneumonia. Curr Opin Infect Dis. 2018;31(2):177\u201386.","journal-title":"Curr Opin Infect Dis."},{"key":"767_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejps.2018.07.004","volume":"122","author":"RL Nation","year":"2018","unstructured":"Nation RL, Theuretzbacher U, Tsuji BT, International Society of Anti-Infective Pharmacology (ISAP). Concentration-dependent plasma protein binding: expect the unexpected. Eur J Pharm Sci. 2018;122:341\u20136.","journal-title":"Eur J Pharm Sci"},{"key":"767_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01174-18","author":"JV Newman","year":"2018","unstructured":"Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother. 2018. \nhttps:\/\/doi.org\/10.1128\/aac.01174-18\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"767_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ijantimicag.2018.01.001","volume":"51","author":"AK Thabit","year":"2018","unstructured":"Thabit AK, Monogue ML, Newman JV, Nicolau DP. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents. 2018;51(5):727\u201332.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"767_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/mdr.2017.0090","volume":"24","author":"Z Daoud","year":"2018","unstructured":"Daoud Z, Farah J, Sokhn ES, El Kfoury K, Dahdouh E, Masri K, et al. Multidrug-resistant Enterobacteriaceae in Lebanese Hospital wastewater: implication in the one health concept. Microb Drug Resist. 2018;24(2):166\u201374.","journal-title":"Microb Drug Resist"},{"issue":"5","key":"767_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/jac\/dkv467","volume":"71","author":"E Bathoorn","year":"2016","unstructured":"Bathoorn E, Tsioutis C, da Silva Voorham JM, Scoulica EV, Ioannidou E, Zhou K, et al. Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call. J Antimicrob Chemother. 2016;71(5):1207\u201312.","journal-title":"J Antimicrob Chemother"},{"issue":"18","key":"767_CR18","first-page":"2568","volume":"123","author":"ZK Sheng","year":"2010","unstructured":"Sheng ZK, Li JJ, Sheng GP, Sheng JF, Li LJ. Emergence of Klebsiella pneumoniae carbapenemase-producing Proteus mirabilis in Hangzhou, China. Chin Med J (Engl). 2010;123(18):2568\u201370.","journal-title":"Chin Med J (Engl)"},{"key":"767_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/aac.01810-18","volume":"63","author":"JV Newman","year":"2019","unstructured":"Newman JV, Zhou J, Izmailyan S, Tsai L. Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019;63:3. \nhttps:\/\/doi.org\/10.1128\/aac.01810-18\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"767_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/03602530600952172","volume":"39","author":"SJ Roffey","year":"2007","unstructured":"Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17\u201343.","journal-title":"Drug Metab Rev"},{"issue":"3","key":"767_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ijantimicag.2018.10.011","volume":"53","author":"D Koulenti","year":"2019","unstructured":"Koulenti D, Song A, Ellingboe A, Abdul-Aziz MH, Harris P, Gavey E, et al. Infections by multidrug-resistant Gram-negative bacteria: what\u2019s new in our arsenal and what\u2019s in the pipeline? Int J Antimicrob Agents. 2019;53(3):211\u201324.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"767_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/21505594.2016.1207834","volume":"8","author":"JT Thaden","year":"2017","unstructured":"Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):403\u201316.","journal-title":"Virulence."},{"issue":"1","key":"767_CR23","first-page":"139","volume":"7","author":"JX Zheng","year":"2018","unstructured":"Zheng JX, Lin ZW, Sun X, Lin WH, Chen Z, Wu Y, et al. Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae. Emerg Microbes Infect. 2018;7(1):139.","journal-title":"Emerg Microbes Infect."},{"issue":"21","key":"767_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.21037\/atm.2017.08.15","volume":"5","author":"PM Honore","year":"2017","unstructured":"Honore PM, Spapen HD. Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited! Ann Transl Med. 2017;5(21):425.","journal-title":"Ann Transl Med"},{"issue":"3","key":"767_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224\u201332.","journal-title":"JAMA Surg."},{"issue":"11","key":"767_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","volume":"23","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23(11):1575\u201384.","journal-title":"Expert Opin Investig Drugs"},{"key":"767_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029","author":"JS Solomkin","year":"2018","unstructured":"Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2018. \nhttps:\/\/doi.org\/10.1093\/cid\/ciy1029\n\n.","journal-title":"Clin Infect Dis"},{"key":"767_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/2277-9175.124642","volume":"3","author":"PC Tripathi","year":"2014","unstructured":"Tripathi PC, Gajbhiye SR, Agrawal GN. Clinical and antimicrobial profile of Acinetobacter spp.: an emerging nosocomial superbug. Adv Biomed Res. 2014;3:13.","journal-title":"Adv Biomed Res"},{"issue":"5","key":"767_CR29","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2017.8.FOCUS17443","volume":"43","author":"N Mohammed","year":"2017","unstructured":"Mohammed N, Savardekar AR, Patra DP, Narayan V, Nanda A. The 21st-century challenge to neurocritical care: the rise of the superbug Acinetobacter baumannii: a meta-analysis of the role of intrathecal or intraventricular antimicrobial therapy in reduction of mortality. Neurosurg Focus. 2017;43(5):E8.","journal-title":"Neurosurg Focus"},{"issue":"1","key":"767_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","volume":"51","author":"H Seifert","year":"2018","unstructured":"Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51(1):62\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"767_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.12.001","author":"A Raz-Pasteur","year":"2018","unstructured":"Raz-Pasteur A, Liron Y, Amir-Ronen R, Abdelgani S, Ohanyan A, Geffen Y, et al. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study. J Glob Antimicrob Resist. 2018. \nhttps:\/\/doi.org\/10.1016\/j.jgar.2018.12.001\n\n.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"767_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12866-018-1349-7","volume":"18","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bai B, Xu GJ, Lin ZW, Li GQ, Chen Z, et al. Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance. BMC Microbiol. 2018;18(1):211.","journal-title":"BMC Microbiol."},{"issue":"21","key":"767_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.21037\/atm.2018.10.29","volume":"6","author":"G Poulakou","year":"2018","unstructured":"Poulakou G, Lagou S, Karageorgopoulos DE, Dimopoulos G. New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. Ann Transl Med. 2018;6(21):423.","journal-title":"Ann Transl Med."},{"issue":"4","key":"767_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2017.05.006","volume":"88","author":"S Mancini","year":"2017","unstructured":"Mancini S, Kieffer N, Poirel L, Nordmann P. Evaluation of the RAPIDEC\u00ae CARBA NP and \u03b2-CARBA\u00ae tests for rapid detection of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2017;88(4):293\u20137.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00767-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T23:25:30Z","timestamp":1588375530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00767-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00767-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"3 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matthew W. McCarthy has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}